ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Inosine Monophosphate

Also written as “H5 Flu Investigational Medical Product (IMP) 1”, “GRT7040” and “IMP”.

Its studies are mostly in Osteoarthritis · Respiratory Syncytial Virus Infections · Acute Pain · Surgical Wound Infection, led by 4 companies.

Drug pageInosine Monophosphate: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 11, 20155 company-led studies, 3 open or runningNext primary completion: Apr 4, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizerits history only20 open or runningphase 3since Nov 11, 2015Nov 11, 2015none ahead
Grünenthalits history only11 open or runningphase 2since Sep 2, 2026Sep 2, 2026Sep 2027phase 2 · NCT07807644
MB PHARMA s.r.o.its history only11 open or runningphase 2since Mar 13, 2024Mar 13, 2024none ahead
Sanofi11 open or runningphase 1since Mar 31, 2026Mar 31, 2026Apr 4, 2027phase 1 · NCT07516418

Also a collaborator on its studies: Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 31, 2026First study: phase 1 study in Respiratory Syncytial Virus InfectionsFirst studyNCT07516418 · 360 enrolled · Australia

Ahead

  1. Apr 4, 2027Primary completion: phase 1 study in Respiratory Syncytial Virus InfectionsNCT07516418

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Sanofi leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07516418Respiratory Syncytial Virus Infections · Australia1Active, not recruitingApr 4, 2027360

How it is read

Names in the registry

  • “H5 Flu Investigational Medical Product (IMP) 1”, 1 entry
  • “GRT7040”, 1 entry
  • “IMP”, 1 entry
  • “Investigational medical product (IMP) administered in parent study”, 1 entry
  • “Investigational Medical Product (IMP) administered in parent study”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.